Argos HIV immunotherapy misses main goal in study

January 9, 2015 12:46 PM

4 0

(Reuters) - Argos Therapeutics Inc said its experimental immunotherapy was unsuccessful in treating HIV-infected patients, raising doubts about its technology platform and sending its stock plunging as much as 31 percent on Friday.

The mid-stage study aimed to reduce the median viral load in HIV-infected patients compared with a placebo.

Also read: BOJ Kuroda: To adjust policy as needed to hit 2 percent price goal

Read more

To category page